Evidence map›Paper›PMID 36172952›Full record

ArticleJournal of the American Heart Association2022

Protein Kinase D1 Regulates Cardiac Hypertrophy, Potassium Channel Remodeling, and Arrhythmias in Heart Failure.

Julie Bossuyt, Johanna M Borst, Marie Verberckmoes, Logan R J Bailey, Donald M Bers, Bence Hegyi

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Molecular mechanisms and intervention approaches of heart failure (Review).International journal of molecular medicine · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Ion channel trafficking implications in heart failure.Frontiers in cardiovascular medicine · 2024
    Review
  10. Cardiac Protein Kinase D1 ablation alters the myocytes β-adrenergic response.Journal of molecular and cellular cardiology · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Julie BossuytDepartment of Pharmacology University of California Davis CA.ORCID 0000-0001-8874-4765
Johanna M BorstDepartment of Pharmacology University of California Davis CA.ORCID 0000-0002-1838-0852
Marie VerberckmoesDepartment of Pharmacology University of California Davis CA.
Logan R J BaileyDepartment of Pharmacology University of California Davis CA.ORCID 0000-0001-7811-7362
Donald M BersDepartment of Pharmacology University of California Davis CA.ORCID 0000-0002-2237-9483
Bence HegyiDepartment of Pharmacology University of California Davis CA.ORCID 0000-0003-3113-221X
University of California, Davis · US

Funding

Project 3 (Mercola)P01HL141084 · NHLBI · STANFORD UNIVERSITY · PI Joseph C. Wu · 2019 to 2026
$21.1M
CaMKII activation and regulation in adult cardiac myocytesR01HL142282 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERS, DONALD M, BOSSUYT, JULIE B · 2018 to 2025
$5.4M
NHLBI NIH HHS P01 HL141084NHLBI NIH HHS R01 HL142282
6 · The paper itself

Abstract

Background Structural and electrophysiological remodeling characterize heart failure (HF) enhancing arrhythmias. PKD1 (protein kinase D1) is upregulated in HF and mediates pathological hypertrophic signaling, but its role in K+ channel remodeling and arrhythmogenesis in HF is unknown. Methods and Results We performed echocardiography, electrophysiology, and expression analysis in wild-type and PKD1 cardiomyocyte-specific knockout (cKO) mice following transverse aortic constriction (TAC). PKD1-cKO mice exhibited significantly less cardiac hypertrophy post-TAC and were protected from early decline in cardiac contractile function (3 weeks post-TAC) but not the progression to HF at 7 weeks post-TAC. Wild-type mice exhibited ventricular action potential duration prolongation at 8 weeks post-TAC, which was attenuated in PKD1-cKO, consistent with larger K+ currents via the transient outward current, sustained current, inward rectifier K+ current, and rapid delayed rectifier K+ current and increased expression of corresponding K+ channels. Conversely, reduction of slowly inactivating K+ current was independent of PKD1 in HF. Acute PKD inhibition slightly increased transient outward current in TAC and sham wild-type myocytes but did not alter other K+ currents. Sham PKD1-cKO versus wild-type also exhibited larger transient outward current and faster early action potential repolarization. Tachypacing-induced action potential duration alternans in TAC animals was increased and independent of PKD1, but diastolic arrhythmogenic activities were reduced in PKD1-cKO. Conclusions Our data indicate an important role for PKD1 in the HF-related hypertrophic response and K+ channel downregulation. Therefore, PKD1 inhibition may represent a therapeutic strategy to reduce hypertrophy and arrhythmias; however, PKD1 inhibition may not prevent disease progression and reduced contractility in HF.

Indexed as

Heart FailurePotassium ChannelsProtein Kinase CAction PotentialsAnimalsArrhythmias, CardiacCardiomegalyMiceMyocytes, CardiacPotassiumPotassiumPotassium ChannelsProtein Kinase Cprotein kinase Daction potentialcardiac arrhythmiaheart failurehypertrophic signalingpotassium channels

Identifiers

PMID36172952
PMCPMC9673734
OpenAlexW4297965286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.